

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Laquinimod for treating relapsing-remitting multiple sclerosis

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Teva Pharmaceuticals (laquinimod) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • Brain and Spine Foundation • Disability Rights UK • Equalities National Council • Independent Age • Leonard Cheshire Disability • Multiple Sclerosis National Therapy Centres • Multiple Sclerosis Resource Centre • Multiple Sclerosis Society • Multiple Sclerosis Trust • Muslim Council of Britain • Muslim Health Network • Neurological Alliance • Neurosupport • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • British Association for Services to the Elderly • British Geriatrics Society • British Neuropathological Society • British Society of Rehabilitative Medicine • Chartered Society of Physiotherapy • College of Occupational Therapist • Institute of Neurology 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Health Research Authority • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium • Wales Neurological Alliance <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Bayer (interferon beta-1b) • Biogen Idec (interferon beta-1a, natalizumab) • Elan Pharma International (natalizumab) • Merck Serono (interferon beta-1a) • Novartis Pharmaceuticals UK (fingolimod, interferon beta-1b) • Teva Pharmaceuticals (glatiramer acetate)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Primary Care Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Therapists in MS (TIMS) • United Kingdom Clinical Pharmacy Association • United Kingdom Multiple Sclerosis Specialist Nurse Association (UKMSSNA) <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Norfolk and Great Yarmouth & Waveney PCT Cluster • Outer North East London PCT Cluster • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research Trust • Cochrane Multiple Sclerosis Group • MRC Clinical Trials Unit • National Institute for Health Research • Research Institute for the Care of Older People <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Kleijnen Systematic Reviews • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • tbc

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

